Flow Cytometry:B-lymphoid lineage assignment: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 24: | Line 24: | ||
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker option 2''' | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker option 2''' | ||
|- | |- | ||
|colspan=" | |colspan="2" style = "font-size:90%; color:black;"|'''Required''' [[CD19|Weak expression of CD19]]</br>'''Required also''' TWO of either: [[CD10]], [[CD22]], or [[CD79a]] (surface or cytoplasmic) | ||
|- | |- | ||
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker option 3''' | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker option 3''' | ||
|- | |- | ||
|colspan=" | |colspan="2" style = "font-size:90%; color:black;"|[[CD19|CD19 is not expressed]]</br>'''In this rare occurrence then requires''' THREE of either: [[CD10]], [[CD22]], or [[CD79a]] (surface or cytoplasmic) | ||
|- | |- | ||
|} | |} |
Revision as of 20:18, 5 January 2024
Requirements to assign B-lymphoid lineage
| |
---|---|
Marker option 1 | |
Required Strong expression of CD19 Required also ONE of either: CD10, CD22, or CD79a (surface or cytoplasmic) | |
Marker option 2 | |
Required Weak expression of CD19 Required also TWO of either: CD10, CD22, or CD79a (surface or cytoplasmic) | |
Marker option 3 | |
CD19 is not expressed In this rare occurrence then requires THREE of either: CD10, CD22, or CD79a (surface or cytoplasmic) |
Notes on interpretation of B-lineage
CD19 is considered by WHO to have high but not complete specificity for B-lineage. Its’ use requires the intensity of expression to be considered: “strong” CD19 expression should exceed 50% of the level seen on normal B progenitors in at least some of the leukaemic cells, while weaker CD19 expression has lower specificity and requires stronger additional evidence of B-lineage commitment (see Table above). Note also: (1) CD79a has frequent expression in T-LL/LBL, so should not be used to suggest B-lineage if that disorder is considered. (2) PAX5 identified by immunohistochemistry has a low evidence base in MPAL diagnosis so should be interpreted with caustion. (3) In the absence of CD19 expression, B-lineage may still be assigned if three other B antigens are expressed.